SCHEMBL2275157

SCHEMBL2275157

COc1ccc(CN2C(=O)CC3CCC(Nc4c(N)cnc5c4ccn5S(=O)(=O)c4ccccc4)CC32)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
TP53 P04637 2/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HTR6 P50406 7/20 0.34
F2 P00734 1/20 0.34
EGLN1 Q9GZT9 1/20 0.33
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33
HTR7 P34969 1/20 0.33
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
PDE9A O76083 1/20 0.32
HPGD P15428 1/20 0.32
LMNA P02545 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2272303 0.90 KDM4E (0.37) ALDH1A1KDM4EPOLBTP53MEN1
SCHEMBL2282644 0.86 KDM4E (0.41) ALDH1A1KDM4EPOLBTP53HTR6
SCHEMBL2276884 0.80 POLB (0.40) ALDH1A1KDM4EPOLBTP53MEN1
SCHEMBL2225853 0.79 ALDH1A1 (0.39) ALDH1A1KDM4EPOLBTP53MEN1
SCHEMBL2272155 0.76 KDM4E (0.39) ALDH1A1KDM4EPOLBTP53HTR6
SCHEMBL14644056 0.74 PIK3C3 (0.36) MEN1KMT2AHTR6DRD2HTR2A
SCHEMBL2278296 0.72 CYP2C19 (0.37) HTR6DRD2HTR2A
SCHEMBL14643457 0.72 CYP2C19 (0.37) HTR6DRD2HTR2AHTR7
SCHEMBL2275159 0.72 JAK2 (0.36) ALDH1A1KDM4EPOLBTP53
SCHEMBL24491105 0.71 CYP2C19 (0.37) ALDH1A1HTR6DRD2HTR2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461328-B2 Tricyclic heterocyclic compounds, compositions and methods of use thereof GENENTECH, INC. (US) 2013-06-11 US disclosed
EP-2523957-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF F. Hoffmann-La Roche AG (CH) 2012-11-21 EP disclosed
US-20110201593-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2011-08-18 US disclosed
WO-2011086053-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201593-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF CCNY, CCNA1, CCNA2 ALDH1A1 1168/4885KDM4E 2333/4885POLB 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.